Madrigal制药 MDGL 深 沪
已收盘 12-12 16:00:00 美东时间
571.44
+0.110
+0.02%
华盛通- 最 高577.21
- 今 开570.11
- 成交量 17.75万股
- 最 低 561.05
- 昨 收 571.33
- 总市值 129.78亿
- 52周最高 605.00
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 265.00
- 委 比 89.13%
- 总股本 2271.14万
- 历史最高 605.00
- 量 比 0.61
- 振 幅 2.83%
- 历史最低 5.25
- 每 手 1
- 风险率 82.71%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 绩后分化！甲骨文遭14家大行集体下调目标价；新思科技、Planet获多家机构上调目标价！
今日重点评级关注：HC Wainwright & Co.：维持Moleculin Biotech"买入"评级，目标价从4美元升至22美元；HC Wainwright & Co.：上调Soluna Holdings评级至"买入"，目标价5美元
12-12 10:24
美股盘后 | Lululemon Athletica涨10.71%，阿利根尼涨3.86%
Lululemon Athletica涨10.71%；阿利根尼涨3.86%；Roivant Sciences Ltd Ordinary Shares涨2.61%
12-12 07:12
B. Riley Securities Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $670
B. Riley Securities analyst William Woods maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and raises the price target from $560 to $670.
12-12 01:01
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals granted equity awards to 24 new non-executive employees on December 1, 2025, under its 2025 Inducement Plan. The awards include options for 4,099 shares and 14,630 restricted stock units, with an exercise price of $579.45 per share. Options vest 25% after one year and 6.25% each quarter thereafter, while restricted stock units vest in four equal yearly installments. The company focuses on developing therapeutics for metab...
12-04 21:05
美股11月涨跌榜 | Lumentum累涨61%！受益谷歌AI需求爆发；“锂矿龙头”美国雅保月涨32%
AI需求爆发！光通信龙头Lumentum累涨61%，为谷歌第二大客户；锂矿公司美国雅保月涨32%，储能与AI需求推动碳酸锂价格飙升>>
11-29 15:39
美股大行评级 | 最高130美元！11家大行集体上调沃尔玛目标价；戴康工业、Gap、罗斯百货等均或多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Fractyl Health"买入"评级，目标价从6美元升至8美元；HC Wainwright & Co.：维持MediWound"买入"评级，目标价从31美元升至36美元
11-24 11:23
美股大行评级 | 最高352美元！14家机构连夜上调英伟达目标价；劳氏、塔吉特、Wix.com等遭多家机构下调目标价
今日重点评级关注：Ascendiant Capital：维持Aclarion"买入"评级，目标价从22美元升至23美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从24美元升至26美元
11-21 15:50
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals granted equity awards to three new non-executive employees under its 2025 Inducement Plan, totaling 2,125 time-based restricted stock units, which vest annually over four years. The company, focused on developing treatments for metabolic dysfunction-associated steatohepatitis (MASH), has its drug Rezdiffra approved for MASH with moderate to advanced fibrosis, with ongoing trials for compensated MASH cirrhosis.
11-20 21:05
美股大行评级 | 高盛上调百度、美敦力、晶科能源等多只个股目标价；家得宝遭9家机构下调目标价；
今日重点评级关注：富国银行：维持Annexon"超配"评级，目标价从14美元升至27美元；瑞穗：上调Relmada Therapeutics评级至"跑赢大市"，目标价从1美元升至10美元
11-20 10:28
Truist Securities Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $640
Truist Securities analyst Srikripa Devarakonda maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and raises the price target from $580 to $640.
11-20 01:50
